Fundacao Champalimaud — CureCurrent

How to interpret these research links

Connected source records

The exact organization name Fundacao Champalimaud appears in 13 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials13

Recruiting shown2

Roles2

SourceClinicalTrials.gov

Clinical trials

13 shown

In Vivo Cortical Excitability Modulation in Major Depressive DisorderNCT05441969 · lead sponsor · 2020-05-19

Single-Dose Image-Guided Radiotherapy With Urethral Sparing and DIL Boost for Intermediate-Risk Prostate Cancer (PROSINT II)NCT04035642 · lead sponsor · 2019-06-01

Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With PembrolizumabNCT06371807 · lead sponsor · 2024-07-01

NOT_YET_RECRUITING

Immersive Meditation for Managing Preoperative Distress.NCT07785245 · lead sponsor · 2024-01-31

Comparing Decision on Aesthetics After Breast Cancer Locoregional Treatment.NCT05196269 · lead sponsor · 2023-08-08

ACTIVE_NOT_RECRUITING

Resistance vs. Aerobic Training on Breast Cancer Patients Undergoing Neoadjuvant TreatmentNCT05297773 · lead sponsor · 2022-12-16

Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate CancerNCT04031378 · lead sponsor · 2019-09-01

Stereotactic Hypofractionated Accelerated Radiotherapy Post-ProstatectomyNCT02976402 · lead sponsor · 2016-11-01

Phase II Study of Ultra-high-dose Hypofractionated vs. Single-dose Image-Guided Radiotherapy for Prostate CancerNCT02570919 · lead sponsor · 2015-09-01

Hypofractionated Image-Guided Radiotherapy (IGRT) With Organ Motion Mitigation and Urethral Sparing for Prostate CancerNCT02761889 · lead sponsor · 2013-05-01

An AI Platform Integrating Imaging Data and Models, Supporting Precision Care Through Prostate Cancer's ContinuumNCT05384002 · collaborator · 2021-02-24

Predicting Effective Adaptation to Breast Cancer to Help Women to BOUNCE BackNCT05095675 · collaborator · 2018-12-06

Long-term Follow-up of the TAM-01 Study and Pooled Analysis of Low-dose Tamoxifen Studies in Non-invasive or Microinvasive Breast NeoplasmsNCT06982313 · collaborator · 1996-07-01

Drugs studied in this sponsor's trials

1 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Fundacao Champalimaud as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

pembrolizumab Injection RxCUI 1657745 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor10

collaborator3

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.